Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
← catalyst calendarNCT07325292 · readout in 330 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
160estimated
Sites
38
Countries
Belgium, China, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-14 | actual | When the study began enrolling |
| Primary completion | 2027-07-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis
Interventions
- Drug: Frexalimab — also filed as SAR441344
- Drug: Frexalimab — also filed as SAR441344
- Drug: MRI contrast-enhancing preparations
Primary outcomes
what the primary-completion date above is the date OFArea under the curve over the interval W20 to W24(part A)
measured Until Week 24
Trough concentration at steady state(part A)
measured Until Week 24
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed